Merck KGaA’s MilliporeSigma announced a definitive agreement to acquire the chromatography business of JSR Life Sciences, broadening its downstream processing portfolio with JSR’s Protein A resins (Amsphere A3 and A+). The acquisition, expected to close by end‑Q2 2026, brings additional Protein A expertise and aims to support scalable monoclonal antibody purification capabilities worldwide. JSR’s chromatography business—based in Belgium and known for its Protein A technologies—adds capacity and product breadth to MilliporeSigma’s offerings for mAb and biologic manufacturers. The deal reflects ongoing consolidation in bioprocessing as manufacturers seek integrated, high‑yield purification solutions to accelerate biologics scale‑up. The transaction signals continued strategic M&A to shore up critical downstream tools amid growing demand for antibody and complex protein therapies.